Moderna, Inc. filings document the regulatory, financial and governance record of a commercial-stage mRNA biotechnology company. Form 8-K reports cover operating results, Regulation FD updates, FDA communications for investigational vaccine submissions, material agreements, patent-litigation settlements and financing arrangements tied to the company's vaccine and therapeutic portfolio.
Proxy and annual-meeting filings disclose board elections, shareholder voting results, executive compensation and governance provisions, including bylaw amendments. The filings also record capital-structure matters such as credit facilities, risk and disclosure controls around pipeline development, and formal updates related to products including Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX.
Moderna, Inc. filing a Rule 144 notice regarding the proposed sale of 53,336 shares of Common Stock through Fidelity Brokerage Services on 05/15/2026. The excerpt also records a prior sale by Stephen Hoge of 160,009 shares on 02/23/2026, with cash considerations shown.
Moderna, Inc. reported governance updates from its May 6, 2026 board actions and annual stockholder meeting. The board amended the company’s Second Amended and Restated By-Laws to designate the federal district courts of the United States as the exclusive forum for Securities Act of 1933 claims, unless the company agrees otherwise in writing.
At the 2026 Annual Meeting, stockholders elected Class II directors Sandra Horning, M.D. and Abbas Hussain for three-year terms. Stockholders also approved, on a non-binding advisory basis, the compensation of the named executive officers and voted to hold future say-on-pay votes every year. In addition, stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Moderna, Inc. director David M. Rubenstein reported new equity awards. On May 6, 2026, he received 2,092 restricted stock units, each convertible into one share of common stock.
He was also granted 9,681 stock options with an exercise price of $48.79 per share, expiring on May 6, 2036. Both the RSUs and options vest in full on the earlier of May 6, 2027 or Moderna's next Annual Meeting of Shareholders, subject to his continued service.
Moderna, Inc. director Hussain Abbas received a grant of 8,371 restricted stock units on May 6, 2026 as equity compensation. These restricted stock units convert into common stock on a one-for-one basis. The award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to his continued service.
Moderna director Sandra Horning received new equity awards in the form of restricted stock units and stock options. On May 6, 2026 she was granted 2,092 restricted stock units and 9,681 stock options with an exercise price of $48.79 per share, each linked to Moderna common stock.
The restricted stock units convert into common stock on a one-for-one basis and will vest in full on the earlier of May 6, 2027 or Moderna's next Annual Meeting of Shareholders, subject to her continued service. The stock options will become fully vested and exercisable on the same schedule and conditions.
NABEL ELIZABETH G reported acquisition or exercise transactions in this Form 4 filing.
Moderna, Inc. director Elizabeth G. Nabel received an award of 8,371 restricted stock units, each convertible into one share of common stock. The units will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, contingent on her continued service.
Moderna, Inc. director Nader Francois reported equity compensation awards. He received 4,185 restricted stock units and a stock option for 6,454 shares of common stock, both granted at no cost on May 6, 2026. The option has a $48.79 exercise price and expires on May 6, 2036.
Both the stock option and the RSUs vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to his continued service. Following these grants, his reported derivative holdings from these awards match the granted amounts.
Moderna, Inc. director Elizabeth E. Tallett received a grant of 8,371 restricted stock units on May 6, 2026. Each restricted stock unit converts into one share of Moderna common stock.
The 8,371 units will vest in full on the earlier of May 6, 2027 or Moderna's next Annual Meeting of Shareholders, as long as she continues serving the company. Following this grant, her reported direct holding from this award is 8,371 restricted stock units.
Moderna, Inc. director Noubar Afeyan received a grant of stock options covering 12,908 shares of common stock. The options have an exercise price of $48.79 per share and expire on May 6, 2036.
According to the terms, this option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to his continued service. Following this grant, Afeyan holds 12,908 stock options directly in this award.